Skip to main content

CASE REPORT article

Front. Med.
Sec. Dermatology
Volume 12 - 2025 | doi: 10.3389/fmed.2025.1512673

Erlotinib Therapy for Olmsted Syndrome with p.L655P Missense Mutation in the TRPV3 Gene: A Case Report

Provisionally accepted
Jia Zhang Jia Zhang 1Mengyue Guo Mengyue Guo 1Dongyang Yuan Dongyang Yuan 1Jinyang Wei Jinyang Wei 1Hongzhou Cui Hongzhou Cui 1,2*
  • 1 Changzhi People's Hospital, Changzhi, China
  • 2 Department of Dermatology, First Hospital of Shanxi Medical University, Taiyuan, Shanxi Province, China

The final, formatted version of the article will be published soon.

    Olmsted syndrome (OS) is a rare disorder characterized by a mutilating palmoplantar keratoderma and periorificial keratotic plaques, but which shows considerable clinical heterogeneity. Recently, transient receptor potential vanilloid 3 (TRPV3) mutations associated with autosomal dominant or recessive OS have been reported. Here we describe a classically OS case with definitive diagnosis of OS based on clinical features and a genetic assay. Genetic analysis revealed heterozygous variants in the TRPV3 gene using whole-exome sequencing of case-parents' trios. This mutation was not identified in his mother. Notably, a previously unreported heterozygous frameshift mutation, c.1964T>C (p.L655P), was identified in exon 15 of the TRPV3 gene in this patient and his father. Additionally, the patient was effectively managed with oral erlotinib at a daily dose of 75mg. After 3 months of treatment, most plantar lesions resolved, and the pain experienced was mildly alleviated. No significant adverse effects were observed in this case during treatment. In addition, we review the OS literature regarding TRPV3 gene mutations.

    Keywords: No.502, Changxing Middle Road, Luzhou District, Changzhi city, 030000, China Keywords:Olmsted syndrome, erlotinib, TRPV3 gene

    Received: 17 Oct 2024; Accepted: 02 Jan 2025.

    Copyright: © 2025 Zhang, Guo, Yuan, Wei and Cui. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Hongzhou Cui, Changzhi People's Hospital, Changzhi, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.